Last reviewed · How we verify

ERYtech Pharma — Portfolio Competitive Intelligence Brief

ERYtech Pharma pipeline: 1 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
L-asparaginase L-asparaginase marketed Enzyme (asparagine depleting agent) Asparagine (substrate depletion mechanism) Oncology
Irinotecan plus 5-FU plus leucovorin Irinotecan plus 5-FU plus leucovorin phase 3 Chemotherapy combination (topoisomerase I inhibitor + antimetabolite + folate cofactor) Topoisomerase I, thymidylate synthase Oncology
Gemcitabine plus Abraxane Gemcitabine plus Abraxane phase 3 Chemotherapy combination (nucleoside analog + taxane) DNA synthesis (gemcitabine); tubulin/microtubules (paclitaxel) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Central European Cooperative Oncology Group · 1 shared drug class
  2. First Affiliated Hospital of Zhejiang University · 1 shared drug class
  3. Hansoh BioMedical R&D Company · 1 shared drug class
  4. Pancreatic Cancer Action Network · 1 shared drug class
  5. Rigshospitalet, Denmark · 1 shared drug class
  6. Verastem, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ERYtech Pharma:

Cite this brief

Drug Landscape (2026). ERYtech Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/erytech-pharma. Accessed 2026-05-14.

Related